Why Peptides Are Suddenly Everywhere
Search “peptides” today and you will find them sold for injury recovery, ageing, energy, immunity - and increasingly, for cancer. Some of that enthusiasm is earned. A great deal of it is not.
The difficulty is that the word “peptide” now covers two completely different things: rigorously tested medicines that have gone through clinical trials and regulatory approval, and unregulated products sold online with borrowed scientific credibility. Both are called peptides. Only one category has evidence behind it.
For someone facing a cancer diagnosis, that distinction matters enormously - and it is almost never made clearly. So let us make it.
What a Peptide Actually Is
A peptide is simply a short chain of amino acids - a very small protein. Your body manufactures thousands of them and uses them as chemical messengers: hormones, immune signals, growth regulators.
What makes peptides genuinely interesting in cancer medicine is precision. Because they are small and specific, a peptide can be designed to recognise one particular target on a cancer cell and act only there - delivering something, blocking something, or flagging that cell for the immune system. That is close to the opposite of conventional chemotherapy’s whole-body approach.
That precision is real, and it has produced some of the most impressive results in modern oncology.
The Peptides That Are Genuinely Proven
Peptide receptor radionuclide therapy. This is peptide medicine at its most striking. A peptide is chemically linked to a radioactive particle and injected. The peptide seeks out and docks onto a specific receptor displayed by neuroendocrine tumour cells, and the radiation destroys the cell from within - while largely sparing tissue that does not carry that receptor. In the NETTER-1 phase III trial it significantly improved progression-free survival; the later NETTER-2 trial showed benefit when used as a first-line therapy. This is approved, mainstream, specialist-administered oncology.
Peptide hormone therapies. Less discussed but longer established. LHRH and GnRH agonists have been standard treatment in prostate and breast cancer for decades. Somatostatin analogues control symptoms in neuroendocrine tumours. These are peptides doing quiet, reliable work in hospitals every day.
Thymosin alpha-1. An immune-regulating peptide, approved in roughly 35 countries. It acts on immune signalling receptors and stimulates several arms of the immune system, including dendritic cells, natural killer cells and T cells. Clinical studies have reported improved overall survival when it is added to treatment in resected non-small-cell lung cancer and liver cancer, reduced chemotherapy toxicity, and restored immune cell counts in patients whose immunity is suppressed. Note that carefully: every one of those findings is as an addition to conventional cancer treatment.
Peptide cancer vaccines. Moving quickly from theory to evidence. A multi-target peptide vaccine for melanoma durably improved long-term survival in a phase II trial, and personalised vaccines built from a patient’s own tumour mutations have extended survival in glioblastoma patients who mounted strong immune responses. Still emerging - but genuinely promising.
The Peptides Being Sold Without Evidence
Here the picture changes sharply.
The peptides marketed most aggressively online - BPC-157, TB-500, GHK-Cu, epitalon - have no human clinical trials in cancer. Not limited evidence. Not mixed evidence. None.
One deserves specific caution. TB-500 promotes the formation of new blood vessels and increases cell migration. Those are precisely the processes a tumour uses to grow its own blood supply and to spread. There are no human clinical trials, and no long-term carcinogenicity study has been performed. Several clinical sources advise that people with a history of cancer avoid it.
Lactoferrin sits somewhere in between, and honestly so. Laboratory research is genuinely interesting: it binds to the large majority of circulating natural killer cells and enhances their killing activity at low concentrations, and its derivative lactoferricin triggers programmed cell death in cancer cells through a well-mapped pathway - while leaving normal lymphocytes, fibroblasts and blood vessel cells unharmed. That selectivity is the striking part. But human cancer trial data remains thin, and it would be dishonest to present laboratory findings as though they were clinical proof.
One Letter That Changes Everything
Consider two peptides: thymosin alpha-1 and thymosin beta-4.
They share a name. They are both called thymosin. They are sold in overlapping marketplaces, often described in similar language.
One is an approved immune-regulating medicine with clinical evidence as an addition to cancer treatment. The other promotes blood vessel growth and cell migration, has never been tested in a human cancer trial, and raises theoretical concerns for cancer patients.
A single letter separates them - and in most online marketing, that distinction disappears entirely. This is the clearest illustration we can offer of why “peptides” is not a category anyone should buy into as a whole.
The Pattern Worth Noticing
Read across all of the credible evidence and one pattern stands out clearly:
No peptide has been shown to treat cancer on its own.
Every therapy that works - radionuclide therapy, hormone therapy, thymosin alpha-1, peptide vaccines - works within a treatment strategy. Thymosin alpha-1’s survival findings appear when it is added to surgery or chemotherapy. Vaccines are combined with immunotherapy. Radionuclide therapy is delivered under specialist supervision with careful patient selection.
“Take peptide X for your cancer” is not a simplified version of this science. It is a different claim altogether - and it is not one the research supports.
Peptides Alongside Active Treatment
This is where peptides become genuinely interesting in an integrative setting - not as a replacement for treatment, but as support for the patient receiving it.
Cancer treatment asks a great deal of the body. Immune function is frequently suppressed - by the tumour itself, by chemotherapy, by radiotherapy, and by age. A patient’s capacity to respond is not a side issue; it influences tolerance of treatment, recovery between cycles, and quality of life throughout.
Several of the peptides with real evidence act precisely in this space. Thymosin alpha-1 has been studied specifically in patients whose immune function is compromised by tumour burden or treatment - that is the population in which it has been examined most closely. Natural killer cells, the immune system’s first responders against abnormal cells, are a documented target of both thymosin alpha-1 and lactoferrin.
At our clinic in Centurion, treatment is built around metabolic and immune context - our IPTLD protocol works by improving how much medicine reaches cancer cells rather than by increasing dose, and it is structured as a weekly rhythm across several treatments. Supportive strategies, where appropriate, are selected to fit that same picture: the patient’s diagnosis, treatment stage, immune status and what else is running concurrently.
For readers who want to understand the underlying biology in detail - drug transport across cell membranes, intracellular activation, cell-cycle timing - we have written a separate page on the science behind IPTLD.
Why This Is a Clinical Decision, Not a Shopping List
We are deliberately not publishing a list of peptides with doses. That is not caution for its own sake - it is because the decisions genuinely depend on variables that cannot be assessed from a product page:
- Cancer type and receptor status. Radionuclide therapy only works if the tumour actually displays the target receptor. Specificity is the whole point.
- Immune status. The evidence for immune-supporting peptides is concentrated in patients who are immunosuppressed - a different situation from someone with intact immune function.
- Treatment stage. Active treatment, recovery and remission are different contexts with different priorities.
- Interactions. A peptide that promotes blood vessel growth is a poor idea during active disease, whatever its benefits elsewhere.
- Dose. Not intuitive. Lactoferrin’s immune effects differ markedly between low and high concentrations - more is not better, and can be worse.
The Bottom Line
Peptide science is one of the genuinely promising directions in modern oncology. Some peptide therapies are approved medicines producing results that would have seemed remarkable twenty years ago, and the field is moving quickly.
But the gap between what is proven and what is sold is currently very wide - and cancer patients are being marketed to on the strength of research that was never done. If you are considering peptides, the useful questions are simple ones: Has this been tested in humans with cancer? Was it tested on its own, or as part of a treatment plan? And does anyone know how it interacts with the treatment I am already receiving?
If you would like to discuss what the evidence supports for your particular situation, speak to our team. We are always willing to talk through the science honestly - including where it runs out.